Health · 23 views
FDA expands use of Zoryve to include young children with plaque psoriasis
Health 
Story intelligence
Coverage Single outlet Single-outlet story
Views 23 Community interest
Brief read Under 1 min brief 37 words
Summary
The U.S. Food and Drug Administration has approved an expanded indication for Zoryve (roflumilast) cream, 0.3%, for the topical treatment of plaque psoriasis in patients ages 2 and older. The expanded approval was granted to Arcutis Biotherapeutics.
AI summaries can be wrong sometimes—always verify important details using the source article.
How AI & Automation are usedMore from Health
Continue reading recent Health coverage
- An administrative gap delays access to new pancreatic cancer treatmentContinue reading
- The key to successful treatment of primary aldosteronism: Get it earlyContinue reading
- Children with cancer are being saved, but are we breaking them in the process?Continue reading
- Sitting on Japanese tatami mats may reduce anxiety and support task engagementContinue reading
Support HappeningNow
Independent AI-powered news analysis is reader-supported. Your contribution helps cover infrastructure, summaries, and continued platform development.
Support HappeningNow